NASDAQ:TCDA - Tricida Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.67
  • Forecasted Upside: 3.38 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$13.22
▲ +0.04 (0.30%)

This chart shows the closing price for TCDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tricida Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCDA

Analyst Price Target is $13.67
▲ +3.38% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Tricida in the last 3 months. The average price target is $13.67, with a high forecast of $18.00 and a low forecast of $7.00. The average price target represents a 3.38% upside from the last price of $13.22.

This chart shows the closing price for TCDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Tricida. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/18/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/16/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2022The Goldman Sachs GroupLower Price TargetBuy$22.00 ➝ $16.00Low
4/12/2022The Goldman Sachs GroupInitiated CoverageBuy$25.00Low
3/30/2022Needham & Company LLCReiterated RatingBuy$20.00 ➝ $18.00Medium
11/16/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$7.00High
8/10/2021Needham & Company LLCInitiated CoverageBuy$20.00High
9/29/2020JPMorgan Chase & Co.Initiated CoverageUnderweight$8.00High
8/25/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$25.00 ➝ $10.00High
8/24/2020Needham & Company LLCReiterated RatingBuy$44.00 ➝ $20.00High
8/9/2020CowenReiterated RatingBuy$40.00Low
8/6/2020Needham & Company LLCLower Price TargetBuy$50.00 ➝ $44.00Medium
7/16/2020Needham & Company LLCReiterated RatingBuy$50.00High
10/15/2019CowenSet Price TargetBuy$50.00Low
8/12/2019Needham & Company LLCSet Price TargetBuy$50.00Medium
8/8/2019CowenReiterated RatingBuy$50.00High
6/26/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$48.00High
6/25/2019CowenReiterated RatingBuy$50.00Low
5/24/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$50.00Medium
4/1/2019EmpireBoost Price Target$37.00 ➝ $58.00Low
11/9/2018CowenReiterated RatingBuyHigh
7/23/2018CowenInitiated CoverageOutperform$50.00Low
7/23/2018JPMorgan Chase & Co.Initiated CoverageNeutral$34.00Low
7/23/2018The Goldman Sachs GroupInitiated CoverageNeutral$32.00Low
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
3/19/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/18/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/18/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
6/17/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/17/2022
  • 2 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/16/2022

Current Sentiment

  • 2 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Tricida logo
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $13.22
Low: $12.73
High: $13.24

50 Day Range

MA: $10.20
Low: $8.19
High: $13.60

52 Week Range

Now: $13.22
Low: $3.80
High: $13.79

Volume

742 shs

Average Volume

504,005 shs

Market Capitalization

$735.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Tricida?

The following sell-side analysts have issued reports on Tricida in the last twelve months: JPMorgan Chase & Co., Needham & Company LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for TCDA.

What is the current price target for Tricida?

3 Wall Street analysts have set twelve-month price targets for Tricida in the last year. Their average twelve-month price target is $13.67, suggesting a possible upside of 3.4%. Needham & Company LLC has the highest price target set, predicting TCDA will reach $18.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $7.00 for Tricida in the next year.
View the latest price targets for TCDA.

What is the current consensus analyst rating for Tricida?

Tricida currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TCDA will outperform the market and that investors should add to their positions of Tricida.
View the latest ratings for TCDA.

What other companies compete with Tricida?

How do I contact Tricida's investor relations team?

Tricida's physical mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (415) 429-7800 and its investor relations email address is [email protected] The official website for Tricida is www.tricida.com. Learn More about contacing Tricida investor relations.